Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI PatientsBusiness Wire • 09/17/22
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)Business Wire • 09/16/22
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart RecoveryBusiness Wire • 09/13/22
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by ImpellaBusiness Wire • 08/16/22
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*Business Wire • 08/04/22
Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/28/22
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart PumpsBusiness Wire • 06/14/22
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock ConferenceBusiness Wire • 05/31/22
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock OutcomesBusiness Wire • 05/18/22